Malaria Vaccines Market Report 2026

The malaria vaccines market size has grown exponentially in recent years. It will grow from $6.24 billion in 2025 to $8.36 billion in 2026 at a compound annual growth rate (CAGR) of 33.9%. The growth in the historic period can be attributed to high malaria burden in endemic regions, long-standing global malaria eradication initiatives, funding support from international health organizations, limitations of antimalarial drug resistance, early success of first-generation malaria vaccines.

The malaria vaccines market size is expected to see exponential growth in the next few years. It will grow to $27.18 billion in 2030 at a compound annual growth rate (CAGR) of 34.3%. The growth in the forecast period can be attributed to increasing government funding for infectious disease prevention, rising climate-driven expansion of malaria-prone regions, growing demand for long-lasting immunity vaccines, advancements in vaccine research and clinical trials, expansion of immunization coverage in low-income countries. Major trends in the forecast period include expansion of next-generation malaria vaccines, growing focus on pediatric immunization programs, increasing public-private partnerships in vaccine deployment, rising emphasis on multi-antigen and combination vaccines, strengthening of mass vaccination campaigns in endemic regions.

An increase in the incidence of mosquito-related diseases is expected to drive the growth of the malaria vaccine market in the coming years. Mosquito-related diseases encompass a wide range of illnesses transmitted through the bite of an infected mosquito. The malaria vaccine, especially the RTS, S/AS01 (RTS, S) vaccine, helps prevent and mitigate the effects of mosquito-borne infectious diseases by training the immune system to identify and combat the parasite. For example, in December 2024, the UK Health Security Agency (UKHSA), a UK-based government department, reported that the annual malaria report for 2023 recorded 2,106 cases of imported malaria in the UK, representing a 26% increase compared to 2022. Consequently, the growing incidence of mosquito-related diseases is fueling the expansion of the malaria vaccine market.

Major companies operating in the malaria vaccines market are concentrating on developing innovative solutions such as next-generation recombinant vaccines to address the rising demand driven by increasing malaria prevalence, government support, and expanding immunization programs. Next-generation recombinant vaccines utilize advanced genetic engineering techniques to target multiple stages of the malaria parasite's life cycle, offering enhanced immune responses and longer-lasting protection compared to traditional vaccines that typically target a single stage and provide limited efficacy. For example, in October 2025, the Government of the Republic of Zambia introduced the malaria vaccine R21/Matrix-M as part of its Expanded Programme on Immunisation. Developed jointly by the University of Oxford and the Serum Institute of India, this vaccine employs a recombinant protein platform combined with the Matrix-M adjuvant to boost immune response, is administered in a four-dose schedule beginning at 6 months of age, and is designed to complement existing anti-malaria interventions. The vaccine provides higher efficacy rates and aims to protect children in high and moderate transmission districts across Zambia, making a significant contribution to malaria elimination efforts.

In June 2025, Bharat Biotech International Limited (BBIL), an India-based biotechnology company, collaborated with GSK plc to reduce the cost of the world’s first malaria vaccine, RTS,S, for children in endemic countries to under $5. Through this partnership, Bharat Biotech and GSK seek to increase access to life-saving malaria vaccination via process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins, ensuring distribution in 12 African countries by the end of 2025 through routine immunisation programs. GSK plc is a UK-based biopharmaceutical company dedicated to science-driven healthcare solutions.

Major companies operating in the malaria vaccines market are GlaxoSmithKline Plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Sanaria Inc, BioNTech SE, Moderna Inc, Pfizer Inc, Novavax Inc, Takeda Pharmaceutical Company Limited, Sanofi SA, Zydus Lifesciences Limited, Valneva SE, GeoVax Labs Inc, Inovio Pharmaceuticals Inc, Vaxart Inc, CanSino Biologics Inc, Sinovac Biotech Ltd, Clover Biopharmaceuticals Inc, Biological E Limited, Emergent BioSolutions Inc.

North America was the largest region in the malaria vaccines market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the malaria vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have had a limited but noticeable impact on the malaria vaccines market by increasing costs for imported raw materials, manufacturing equipment, and cold-chain components. These effects are most evident in vaccine production and distribution segments, particularly in africa and parts of asia-pacific that rely on international suppliers. Higher tariffs can influence procurement costs for public immunization programs. However, tariffs have also encouraged local vaccine manufacturing, regional production hubs, and technology transfer initiatives, supporting long-term supply security.

The malaria vaccines market research report is one of a series of new reports that provides malaria vaccines market statistics, including malaria vaccines industry global market size, regional shares, competitors with a malaria vaccines market share, detailed malaria vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the malaria vaccines industry. This malaria vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malaria vaccines are specially developed to prevent malaria, a serious mosquito-borne infectious disease caused by parasites of the Plasmodium genus. These vaccines are designed to induce immunity against the Plasmodium parasites responsible for malaria.

The primary agents targeted by malaria vaccines include Plasmodium falciparum, Plasmodium vivax, and Anopheles species. Plasmodium falciparum is a protozoan parasite that causes the most severe and lethal form of malaria in humans. The different types of vaccines include pre-erythrocytic, erythrocytic, multi-antigen, and others, which can be administered via various routes, such as intramuscular, subcutaneous, intradermal, and more. These vaccines are distributed through multiple channels, including public and private networks.

The malaria vaccines market consists of sales of circumsporozoite protein (CSP) antigens, multi-component adjuvants, and circumsporozoite protein. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.